"Taste Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions characterized by an alteration in gustatory function or perception. Taste disorders are frequently associated with OLFACTION DISORDERS. Additional potential etiologies include METABOLIC DISEASES; DRUG TOXICITY; and taste pathway disorders (e.g., TASTE BUD diseases; FACIAL NERVE DISEASES; GLOSSOPHARYNGEAL NERVE DISEASES; and BRAIN STEM diseases).
|Taste Disorder, Primary
- Taste Disorder, Primary
- Primary Taste Disorder
- Primary Taste Disorders
- Taste Disorders, Primary
- Taste, Metallic
- Metallic Taste
- Metallic Tastes
- Tastes, Metallic
Taste Disorder, Secondary
- Taste Disorder, Secondary
- Secondary Taste Disorder
- Secondary Taste Disorders
- Taste Disorders, Secondary
Below are MeSH descriptors whose meaning is more general than "Taste Disorders".
Below are MeSH descriptors whose meaning is more specific than "Taste Disorders".
This graph shows the total number of publications written about "Taste Disorders" by people in this website by year, and whether "Taste Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Taste Disorders" by people in Profiles.
Lyckholm L, Heddinger SP, Parker G, Coyne PJ, Ramakrishnan V, Smith TJ, Henkin RI. A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders. J Pain Palliat Care Pharmacother. 2012 Jun; 26(2):111-4.
Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 01; 67(5):1318-22.